Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR-155/SHIP-1 Signaling Pathway
Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR-155/SHIP-1 Signaling Pathway
复制标题
DOI：
10.1111/1755-5922.12098
复制
发表时间：
2014-12-01
影响因子：
3.1
通讯作者：
Mo, Yingxi
中科院分区：
文献类型：
--
作者：
Xie, Wenchao;Li, Ping;Mo, Yingxi
目的研究瑞舒伐他汀对急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)相关的程序性心肌损伤的保护作用。方法159例接受经皮冠状动脉介入治疗的急性冠脉综合征患者随机分为对照组(安慰剂治疗)和瑞舒伐他汀组(术前12小时给予瑞舒伐他汀20 mg，术前2小时再给予20 mg)。分别于术前和术后24小时检测患者外周血中干扰素、肿瘤坏死因子、IL-6、miR-155/SHIP-1和CD4(+)FoxP3(+)Treg水平。结果与安慰剂相比，瑞舒伐他汀治疗可显著降低围术期心肌梗死(PMI)的发生率和心肌肌钙蛋白I(CTnI)水平，同时降低血清miR-155的相对表达、炎性细胞因子(INF-、TNF-和IL-6)水平、SHIP-1表达和CD4(+)FoxP3(+)Treg百分率(P
PurposeThe beneficial effect of rosuvastatin against percutaneous coronary intervention (PCI) related procedural myocardial injury has been determined mostly in patients with acute coronary syndromes (ACS). However, the detailed therapeutic mechanism has not been well studied.MethodsPatients with ACS receiving PCI (n=159) were randomized to control group (placebo treatment) or to rosuvastatin group (20mg 12h before PCI, and a further 20mg 2h preprocedure dose). Levels of INF-, TNF-, IL-6, miR-155/SHIP-1, and CD4(+)FoxP3(+)Treg in peripheral blood were detected before PCI and 24h after PCI. Clinical data of these patients were also collected in this prospective study.ResultsCompared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR-155, levels of inflammatory cytokines (INF-, TNF-, and IL-6), increased SHIP-1 expression and CD4(+)FoxP3(+)Treg percentage values (P